Cargando…

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substantial proportion of patients either do not respond to treatment or lose response over time. Drug immunogenicity, manifested as the formation of anti-drug antibodies (ADAb), constitute a significant cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gehin, Johanna Elin, Goll, Guro Løvik, Brun, Marthe Kirkesæther, Jani, Meghna, Bolstad, Nils, Syversen, Silje Watterdal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649489/ https://www.ncbi.nlm.nih.gov/pubmed/36315391 http://dx.doi.org/10.1007/s40259-022-00559-1

Ejemplares similares

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
por: Gehin, Johanna Elin, et al.
Publicado: (2019)

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
por: Brun, Marthe Kirkesæther, et al.
Publicado: (2022)

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
por: Gehin, Johanna E., et al.
Publicado: (2021)

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
por: Syversen, Silje W, et al.
Publicado: (2020)

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
por: Syversen, Silje Watterdal, et al.
Publicado: (2022)

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients
por: Syversen, Silje W, et al.
Publicado: (2008)

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
por: Bjørlykke, Kristin H, et al.
Publicado: (2023)

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
por: Jyssum, Ingrid, et al.
Publicado: (2022)

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
por: Jani, Meghna, et al.
Publicado: (2018)

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
por: Jani, Meghna, et al.
Publicado: (2014)

Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
por: Joergensen, Kristin K., et al.
Publicado: (2022)

Investigations of immunogenic, allergenic and adjuvant properties of Cry1Ab protein after intragastric exposure in a food allergy model in mice
por: Andreassen, Monica, et al.
Publicado: (2016)

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
por: Uhlig, Till, et al.
Publicado: (2017)

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice
por: Jani, Meghna, et al.
Publicado: (2016)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Single-Cell Transcriptomics for Unlocking Personalized Cancer Immunotherapy: Toward Targeting the Origin of Tumor Development Immunogenicity
por: Khodayari, Saeed, et al.
Publicado: (2023)

Citrullinated proteins in arthritis: presence in joints and effects on immunogenicity
por: Lundberg, K, et al.
Publicado: (2004)

The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
por: Gjefsen, Elisabeth, et al.
Publicado: (2020)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Personalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway
por: Louro, Javier, et al.
Publicado: (2023)

Impact of a new European regulations on functional food market – an overview
por: Lovik, Martinus
Publicado: (2011)

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
por: Wolf, Asia-Sophia, et al.
Publicado: (2023)

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
por: De Groot, Anne S., et al.
Publicado: (2021)

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
por: Kared, Hassen, et al.
Publicado: (2023)

Pharmacogenetics of Treatment Response in Psoriatic Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

Spatial Distribution of Noise Reduction in Four Iterative Reconstruction Algorithms in CT—A Technical Evaluation
por: Guleng, Anette, et al.
Publicado: (2020)

Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy
por: Varin, Juliette, et al.
Publicado: (2021)

Towards Personalization in the Curative Treatment of Gastric Cancer
por: Slagter, Astrid E., et al.
Publicado: (2020)

Mucosal Metabolomic Profiling and Pathway Analysis Reveal the Metabolic Signature of Ulcerative Colitis
por: Diab, Joseph, et al.
Publicado: (2019)

Antinociceptive Actions of Botulinum Toxin A1 on Immunogenic Hypersensitivity in Temporomandibular Joint of Rats
por: Muñoz-Lora, Victor Ricardo Manuel, et al.
Publicado: (2022)

Albargin Joint Review with Personal Experience
por: Seifert,
Publicado: (1904)

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
por: Briney, Bryan, et al.
Publicado: (2016)

An integrated approach for characterizing immunogenic responses toward a bispecific antibody
por: Cohen, Sivan, et al.
Publicado: (2021)

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis
por: Bluett, James, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_siff6uimdatquacfc3s8mr2plv